Li H
Department of Surgery, Beijing Red Cross Chaoyang Hospital, China.
Eur J Cancer Prev. 1993 Jan;2(1):47-52. doi: 10.1097/00008469-199301000-00008.
Barrett's oesophagus is a pre-malignant condition with an increased risk of adenocarcinoma. The prevalence of adenocarcinoma in Barrett's oesophagus is about 10% but its true incidence in the general population is unknown. The development of adenocarcinoma in Barrett's oesophagus is a multi-step process. Gastro-oesophageal reflux symptoms are absent in many Barrett's patients and both Barrett's oesophagus and adenocarcinoma are usually but not always diagnosed simultaneously. When a carcinoma is identified, the treatment of choice is resection. Three-stage oesophagectomy is considered the most appropriate procedure. The prognosis of Barrett's carcinoma is dismal and the survival rate is related to stage of the tumour. However, encouraging results have been reported in the past 5 years. Endoscopic surveillance for Barrett's oesophagus is still a controversial topic but for some high-risk subgroups of patients regular surveillance is advocated. At the present time, dysplasia is the best available indicator of malignancy in Barrett's oesophagus.
巴雷特食管是一种癌前病变，腺癌风险增加。巴雷特食管中腺癌的患病率约为10%，但其在普通人群中的真实发病率尚不清楚。巴雷特食管腺癌的发生是一个多步骤过程。许多巴雷特患者没有胃食管反流症状，巴雷特食管和腺癌通常但并非总是同时被诊断出来。当发现癌症时，首选治疗方法是切除。三阶段食管切除术被认为是最合适的手术。巴雷特癌的预后很差，生存率与肿瘤分期有关。然而，在过去5年中已有令人鼓舞的结果报道。巴雷特食管的内镜监测仍然是一个有争议的话题，但对于一些高危亚组患者，主张进行定期监测。目前，发育异常是巴雷特食管中现有的最佳恶性肿瘤指标。
